Lilly settles Alaska Zyprexa case for $15 million

Share this article:
Eli Lilly announced a $15 million settlement with the State of Alaska, which sued the company for allegedly withholding information about Zyprexa side effects.

Lilly admitted no wrongdoing. In a statement, Robert Armitage, SVP and general counsel, said: “While we had a strong defense, we agreed with the State that the best result for everyone is an amicable resolution. A trial always involves significant time and resources, especially a two-phase trial like this one that posed additional legal hurdles. A settlement helps us get back to what we want to focus on as a company: developing important new medications through research and partnerships with doctors and patients.”

In addition to the $15 million, Alaska secured an agreement that “will ensure that Alaska is treated as favorably as any other state that may settle with Lilly in the future over similar claims.” The Wall Street Journal reported that before the trial started, Lilly offered a $2 million settlement and the state sought close to $200 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...